Loading…
Loading…
EQUITY / NASDAQ · XNCM
Silo Pharma Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.458 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.458 USD · Volume 1,152,720
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -928,949 USD | -1,248,551 USD | — |
| Net income | -832,829 USD | -1,204,293 USD | — |
| Cash and cash equivalents | 3,277,095 USD | — | — |
| Total liabilities | 1,065,733 USD | — | — |
| Total equity | 4,886,290 USD | 4,917,083 USD | -0.63% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 3,277,095 USD | — | — | 4,748,700 USD | 4,748,700 USD | 3,917,627 USD | — | — |
| Net incomeIncome statement | -832,829 USD | -2,479,946 USD | -1,647,117 USD | — | -4,227,698 USD | -1,110,438 USD | -3,346,168 USD | -1,204,293 USD |
| Operating profitIncome statement | -928,949 USD | -2,523,609 USD | — | — | -4,280,662 USD | -1,151,466 USD | -3,494,138 USD | -1,248,551 USD |
| Total assetsBalance sheet | 5,952,023 USD | — | — | 7,605,100 USD | 7,605,100 USD | 6,384,681 USD | — | — |
| Total equityBalance sheet | 4,886,290 USD | — | 5,681,836 USD | 6,305,441 USD | 6,305,441 USD | 5,008,840 USD | — | 4,917,083 USD |
| Total liabilitiesBalance sheet | 1,065,733 USD | — | — | 1,299,659 USD | 1,299,659 USD | 1,375,841 USD | — | — |
| Financing cash flowCash flow statement | — | -26,997 USD | — | — | 4,860,219 USD | — | 2,728,880 USD | — |
| Gross profitIncome statement | — | -2,662 USD | — | — | 27,807 USD | -2,662 USD | 30,470 USD | 16,566 USD |
| Investing cash flowCash flow statement | — | 159,876 USD | — | — | 644,021 USD | — | 1,164,009 USD | — |
| Operating cash flowCash flow statement | — | -1,604,484 USD | — | — | -4,661,339 USD | — | -3,881,061 USD | — |
| RevenueIncome statement | — | 18,026 USD | — | — | 72,102 USD | 18,025 USD | 54,076 USD | 18,025 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.